These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37631923)

  • 21. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
    Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
    Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ.
    Hayward S; Thompson LA; McEachern A
    J Patient Cent Res Rev; 2016; 3(2):111-115. PubMed ID: 27376105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
    Fernández-Prada M; Brandy-García AM; Rodríguez-Fonseca OD; Huerta-González I; Fernández-Noval F; Martínez-Ortega C
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):97-102. PubMed ID: 29752214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant.
    Malone K; Clark S; Palmer JA; Lopez S; Pradhan M; Furth S; Kim J; Fisher B; Laskin B
    Pediatr Transplant; 2016 Sep; 20(6):783-9. PubMed ID: 27334506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal vaccine uptake among Medicare Beneficiaries aged ≥65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019.
    Vietri J; Sato R; Averin A; Weycker D; Kumar M; Prasad S; Chilson E
    Vaccine; 2023 Aug; 41(36):5211-5215. PubMed ID: 37474408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing a Nurse-Driven Protocol for Pneumococcal Vaccination in an Academic Rheumatology Clinic.
    Joerns EK; Pokala N; Bermas B; Reisch J; Wang DC; Arasaratnam R; Bajaj P
    J Rheumatol; 2023 Mar; 50(3):413-419. PubMed ID: 36319017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta-analysis.
    Britt AF; Poupore NS; Nguyen SA; White DR
    Otolaryngol Head Neck Surg; 2023 Mar; 168(3):291-299. PubMed ID: 35852861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
    Restivo V; Baldo V; Sticchi L; Senese F; Prandi GM; Pronk L; Owusu-Edusei K; Johnson KD; Ignacio T
    Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
    Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
    J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
    Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
    Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
    Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.